Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agenus Inc AGEN

Healthcare Biotechnology
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its... see more

Recent & Breaking News (NDAQ:AGEN)

Agenus to Report Third Quarter 2014 Financial Results on October 31, 2014; Conference Call to Follow

Business Wire October 27, 2014

Agenus Inc. (AGEN) Jumps 5.41% on September 10

Equities.com September 10, 2014

Agenus to Participate in Two Upcoming Investor Conferences

Business Wire September 2, 2014

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014

Business Wire August 11, 2014

Agenus to Present at Cambridge Healthtech Institute's Second Annual Conference on Immunomodulatory Therapeutic Antibodies for Cancer

Business Wire August 4, 2014

GSK announces EU regulatory submission for malaria vaccine candidate RTS,S

Canada NewsWire July 24, 2014

Agenus Reports Second Quarter 2014 Financial Results

Business Wire July 24, 2014

First Vaccine Candidate for Malaria is Accepted for EU Regulatory Review

Business Wire July 24, 2014

Agenus to Report Second Quarter 2014 Financial Results on July 24, 2014; Conference Call to Follow

Business Wire July 17, 2014

Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Analysis

Business Wire July 1, 2014

Agenus Vaccine Shows Significant Reduction in Viral Burden after HerpV Generated Immune Activation

Business Wire June 26, 2014

Agenus to Present at the JMP Securities Healthcare Conference

Business Wire June 19, 2014

Agenus Selected for Inclusion in the Russell 3000 Index and Global Index

Business Wire June 16, 2014

Agenus to Present at Jefferies 2014 Global Healthcare Conference

Business Wire May 30, 2014

Agenus, Inc. - "Checkpoint Modulators and Combination Therapies for Cancer"

Accesswire May 15, 2014

Agenus Reports First Quarter 2014 Financial Results

Business Wire May 8, 2014

Agenus to Report First Quarter 2014 Financial Results on May 8, 2014; Conference Call to Follow

Business Wire April 29, 2014

Agenus Announces Collaboration and License Agreement with Merck for Novel Checkpoint Antibody-Based Cancer Immunotherapies

Business Wire April 28, 2014

Agenus to Host Annual Meeting of Stockholders

Business Wire April 16, 2014

Update on GSK'S MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-Small Cell Lung Cancer

Business Wire April 2, 2014